Cargando…
COVID-19 pandemic: an overview of epidemiology, parthenogenesis, diagnostics and potential vaccines and therapeutics
At the time of writing this review, severe acute respiratory coronavirus syndrome-2 (SARS-CoV-2) has infected more than 2,355,853 patients and resulted in more than 164,656 deaths worldwide (as of 20 April 2020). This review highlights the preventive measures, available clinical therapies and the po...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Newlands Press Ltd
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7222554/ https://www.ncbi.nlm.nih.gov/pubmed/32397911 http://dx.doi.org/10.4155/tde-2020-0035 |
_version_ | 1783533601067892736 |
---|---|
author | Amawi, Haneen Abu Deiab, Ghina'a I A Aljabali, Alaa A Dua, Kamal Tambuwala, Murtaza M |
author_facet | Amawi, Haneen Abu Deiab, Ghina'a I A Aljabali, Alaa A Dua, Kamal Tambuwala, Murtaza M |
author_sort | Amawi, Haneen |
collection | PubMed |
description | At the time of writing this review, severe acute respiratory coronavirus syndrome-2 (SARS-CoV-2) has infected more than 2,355,853 patients and resulted in more than 164,656 deaths worldwide (as of 20 April 2020). This review highlights the preventive measures, available clinical therapies and the potential of vaccine development against SARS-CoV-2 by taking into consideration the strong genetic similarities of the 2003 epidemic SARS-CoV. Recent studies are investigating the repurposing of US FDA-approved drugs as there is no available vaccine yet with many attempts under clinical evaluation. Several antivirals, antimalarials and immunomodulators that have shown activity against SARS-CoV and Middle East coronavirus respiratory syndromes are being evaluated. In particular, hydroxychloroquine, remdesivir, favipiravir, arbidol, tocilizumab and bevacizumab have shown promising results. The main aim of this review is to provide an overview of this pandemic and where we currently stand. |
format | Online Article Text |
id | pubmed-7222554 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Newlands Press Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-72225542020-05-14 COVID-19 pandemic: an overview of epidemiology, parthenogenesis, diagnostics and potential vaccines and therapeutics Amawi, Haneen Abu Deiab, Ghina'a I A Aljabali, Alaa A Dua, Kamal Tambuwala, Murtaza M Ther Deliv Review At the time of writing this review, severe acute respiratory coronavirus syndrome-2 (SARS-CoV-2) has infected more than 2,355,853 patients and resulted in more than 164,656 deaths worldwide (as of 20 April 2020). This review highlights the preventive measures, available clinical therapies and the potential of vaccine development against SARS-CoV-2 by taking into consideration the strong genetic similarities of the 2003 epidemic SARS-CoV. Recent studies are investigating the repurposing of US FDA-approved drugs as there is no available vaccine yet with many attempts under clinical evaluation. Several antivirals, antimalarials and immunomodulators that have shown activity against SARS-CoV and Middle East coronavirus respiratory syndromes are being evaluated. In particular, hydroxychloroquine, remdesivir, favipiravir, arbidol, tocilizumab and bevacizumab have shown promising results. The main aim of this review is to provide an overview of this pandemic and where we currently stand. Newlands Press Ltd 2020-05-13 2020-04 /pmc/articles/PMC7222554/ /pubmed/32397911 http://dx.doi.org/10.4155/tde-2020-0035 Text en © 2020 Newlands Press This work is licensed under the Creative Commons Attribution 4.0 License (http://creativecommons.org/licenses/by/4.0/) |
spellingShingle | Review Amawi, Haneen Abu Deiab, Ghina'a I A Aljabali, Alaa A Dua, Kamal Tambuwala, Murtaza M COVID-19 pandemic: an overview of epidemiology, parthenogenesis, diagnostics and potential vaccines and therapeutics |
title | COVID-19 pandemic: an overview of epidemiology, parthenogenesis, diagnostics and potential vaccines and therapeutics |
title_full | COVID-19 pandemic: an overview of epidemiology, parthenogenesis, diagnostics and potential vaccines and therapeutics |
title_fullStr | COVID-19 pandemic: an overview of epidemiology, parthenogenesis, diagnostics and potential vaccines and therapeutics |
title_full_unstemmed | COVID-19 pandemic: an overview of epidemiology, parthenogenesis, diagnostics and potential vaccines and therapeutics |
title_short | COVID-19 pandemic: an overview of epidemiology, parthenogenesis, diagnostics and potential vaccines and therapeutics |
title_sort | covid-19 pandemic: an overview of epidemiology, parthenogenesis, diagnostics and potential vaccines and therapeutics |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7222554/ https://www.ncbi.nlm.nih.gov/pubmed/32397911 http://dx.doi.org/10.4155/tde-2020-0035 |
work_keys_str_mv | AT amawihaneen covid19pandemicanoverviewofepidemiologyparthenogenesisdiagnosticsandpotentialvaccinesandtherapeutics AT abudeiabghinaai covid19pandemicanoverviewofepidemiologyparthenogenesisdiagnosticsandpotentialvaccinesandtherapeutics AT aaljabalialaaa covid19pandemicanoverviewofepidemiologyparthenogenesisdiagnosticsandpotentialvaccinesandtherapeutics AT duakamal covid19pandemicanoverviewofepidemiologyparthenogenesisdiagnosticsandpotentialvaccinesandtherapeutics AT tambuwalamurtazam covid19pandemicanoverviewofepidemiologyparthenogenesisdiagnosticsandpotentialvaccinesandtherapeutics |